Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.
|Study Design:||Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||PK/PD Study of GW823093 in Japanese Subjects With T2DM A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes|
- Pharmacokinetic and Pharmacodynamic measurements during 7 days of dosing.
- Adverse events Changes in clinical laboratory tests Vital signs 12-lead ECG during 7 days of dosing.
|Study Start Date:||March 2006|
|Study Completion Date:||June 2006|
|Primary Completion Date:||June 2006 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372957
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|